Due to the fact that aberrant HDAC activity has been associated with the occurrence of different types of cancers [5,6], a variety of clinically applicable HDAC inhibitors (HDIs) have been developed and tested during the past few decades [3,7-10]. The gene discussed is HDAC9; the disease is cancer.